经友好协商后，认购人B与本公司于2026年1月30日(交易时段后)订立终止协议，以终止认购协议B。根 据终止协议，认购协议B的订约方须解除及免除其于认购协议B项下各自的义务，且概无任何一方须就 因认购协议B产生或与其有关的任何事宜向另一方提出任何索偿。 由于认购协议B已终止，认购协议A所募集的所得款项总额将约为2999万港元，而所得款项净额将约为 2973万港元。扣除所有相关开支后的认购价净额约为每股认购股份5.31港元。所有所得款项净额拟用于 与血管介入、呼吸介入及肿瘤介入相关的微创介入产品的研发、生产及商业化，以及就该等产品商业化 的潜在海外业务扩张。 康沣生物-B(06922)发布公告，认购协议A的所有条件已获达成，且认购协议A项下交易已于2026年1月 30日完成。总计559.5万股认购股份已成功按每股认购股份认购价5.36港元向认购人A发行及配发。该 559.5万股认购股份相当于紧接认购协议A完成前已发行H股数目约3.90%及现有已发行股份数目约 2.34%;及紧随认购协议A完成后经配发及发行该559.5万股认购股份扩大后已发行H股数目约3.75%及现 有已发行股份数目约2.29%。 ...

Core Viewpoint - 康沣生物-B (06922) has entered into a subscription agreement to issue a total of 7.46 million H shares at a subscription price of HKD 5.36 per share, representing a discount of approximately 17.79% compared to the closing price of HKD 6.52 on the Hong Kong Stock Exchange on the same day [1] Group 1: Subscription Details - The subscription agreement is with LP Investment Holdings Group and Mr. Li Jun [1] - The net proceeds from the subscription are approximately HKD 39.73 million [1] Group 2: Use of Proceeds - 80% of the proceeds will be allocated for research, production, and commercialization of minimally invasive interventional products related to vascular intervention, respiratory intervention, and tumor intervention [1] - 20% of the proceeds will be used for general working capital of the group [1]